Mitogen-Activated Protein Kinases and Their Role in Radiation Response

Genes and Cancer

Volumn 4, Issue 9-10, 2013, Pages 401-408

  Munshi, Anupama ^a   Ramesh, Rajagopal ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

MAP kinases; radiation; signaling pathways

Indexed keywords

ATM PROTEIN; HEAT SHOCK PROTEIN 27; INTERLEUKIN 1; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR;

APOPTOSIS; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DNA END JOINING REPAIR; DOWN REGULATION; HUMAN; IONIZING RADIATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIATION DOSE; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW; STRESS;

EID: 84890487369     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913485414     Document Type: Review

References (107)

1. Mordret G.MAP kinase kinase: a node connecting multiple pathways.Biol Cell. 1993;79:193-207.
2. L'Allemain G.Deciphering the MAP kinase pathway.Prog Growth Factor Res. 1994;5:291-334.
3. Seger R,Krebs EG.The MAPK signaling cascade.FASEB J. 1995;9:726-35.
4. Lewis TS,Shapiro PS,Ahn NG.Signal transduction through MAP kinase cascades.Adv Cancer Res. 1998;7:49-139.
5. Kyriakis JM,Avruch J.Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation.Physiol Rev. 2001;81:807-69.
6. Pearson G,Robinson F,Beers Gibson T, et al.Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions.Endocr Rev. 2001;22:153-83.
7. Raingeaud J,Whitmarsh AJ,Barrett T,Dérijard B,Davis RJ.MKK3- and MKK6-regulated gene expression is mediated by the p38 mitogen- activated protein kinase signal transduction pathway.Mol Cell Biol. 1996;16:1247-55.
8. Su B,Karin M.Mitogen-activated protein kinase cascades and regulation of gene expression.Curr Opin Immunol. 1996;8:402-11.
9. Dent P,Yacoub A,Contessa J, et al.Stress and radiation-induced activation of multiple intracellular signaling pathways.Radiat Res. 2003;159:283-300.
10. Tibbles LA,Woodgett JR.The stress-activated protein kinase pathways.Cell Mol Life Sci. 1999;55:1230-54.
11. Schmidt-Ullrich RK,Dent P,Grant S,Mikkelsen RB,Valerie K.Signal transduction and cellular radiation responses.Radiat Res. 2000;153:245-57.
12. Haimovitz-Friedman A.Radiation-induced signal transduction and stress response.Radiat Res. 1998;150:S102-8.
13. Dent P,Yacoub A,Fisher PB,Hagan MP,Grant S.MAPK pathways in radiation responses.Oncogene. 2003;22:5885-96.
14. Ouwens DM,Gomes de,Mesquita DS,Dekker J, et al.Hyperosmotic stress activates the insulin receptor in CHO cells.Biochim Biophys Acta. 2001;1540:97-106.
15. Stadheim TA,Kucera GL.c-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for mitoxantrone- and anisomycin-induced apoptosis in HL-60 cells.Leuk Res. 2002;26:55-65.
16. Chen YR,Meyer CF,Tan TH.Persistent activation of c-Jun N-terminal kinase 1 (JNK1) in gamma radiation-induced apoptosis.J Biol Chem. 1996;271:631-4.
17. Adam D,Ruff A,Strelow A,Wiegmann K,Krönke M.Induction of stress-activated protein kinases/c-Jun N-terminal kinases by the p55 tumor necrosis factor receptor does not require sphingomyelinases.Biochem J. 1998;333:343-50.
18. Ferrer I,Olive M,Ribera J,Planas AM.Naturally occurring (programmed) and radiation-induced apoptosis are associated with selective c-Jun expression in the developing rat brain.Eur J Neurosci. 1996;8:1286-98.
19. Ferrer I,Olivé M,Blanco R,Cinós C,Planas AM.Selective c-Jun overexpression is associated with ionizing radiation-induced apoptosis in the developing cerebellum of the rat.Brain Res Mol Brain Res. 1996;38:91-100.
20. Verheij M,Ruiter GA,Zerp SF, et al.The role of the stress-activated protein kinase (SAPK/JNK) signaling pathway in radiation-induced apoptosis.Radiother Oncol. 1998;47:225-32.
21. Verheij M,Bose R,Lin XH, et al.Requirement for ceramide-initiated SAPK/JNK signaling in stress-induced apoptosis.Nature. 1996;380:75-9.
22. Brown PH,Alani R,Preis LH,Szabo E,Birrer MJ.Suppression of oncogene-induced transformation by a deletion mutant of c-Jun.Oncogene. 1993;8:877-86.
23. Kim MJ,Lee KH,Lee SJ.Ionizing radiation utilizes c-Jun N-terminal kinase for amplification of mitochondrial apoptotic cell death in human cervical cancer cells.FEBS J. 2008;275:2096-108.
24. Viktorsson K,Ekedahl J,Lindebro MC, et al.Defective stress kinase and Bak activation in response to ionizing radiation but not cisplatin in a non-small cell lung carcinoma cell line.Exp Cell Res. 2003;289:256-64.
25. Lei K,Davis RJ.JNK phosphorylation of Bim-related members of the Bcl2 family induces Bax-dependent apoptosis.Proc Natl Acad Sci U S A. 2003;100:2432-7.
26. Lei K,Nimnual A,Zong WX, et al.The Bax subfamily of Bcl2-related proteins is essential for apoptotic signal transduction by c-Jun NH(2)-terminal kinase.Mol Cell Biol. 2002;22:4929-42.
27. Kharbanda S,Yuan ZM,Weichselbaum R,Kufe D.Determination of cell fate by c-Abl activation in the response to DNA damage.Oncogene. 1998;17:3309-18.
28. Lee SA,Dritschilo A,Jung M.Role of ATM in oxidative stress-mediated c-Jun phosphorylation in response to ionizing radiation and CdCl2.J Biol Chem. 2001;276:11783-90.
29. Hayakawa J,Depatie C,Ohmichi M,Mercola D.The activation of c-Jun NH2-terminal kinase (JNK) by DNA-damaging agents serves to promote drug resistance via activating transcription factor 2 (ATF2)-dependent enhanced DNA repair.J Biol Chem. 2003;278:20582-92.
30. Potapova O,Basu S,Mercola D,Holbrook NJ.Protective role for c-Jun in the cellular response to DNA damage.J Biol Chem. 2001;276:28546-53.
31. Potapova O,Haghighi A,Bost F, et al.The Jun kinase/stress-activated protein kinase pathway functions to regulate DNA repair and inhibition of the pathway sensitizes tumor cells to cisplatin.J Biol Chem. 1997;272:14041-4.
32. MacLaren A,Black EJ,Clark W,Gillespie DAF.c-Jun-deficient cells undergo premature senescence as a result of spontaneous DNA damage accumulation.Mol Cell Biol. 2004;24:9006-18.
33. Gjerset RA,Lebedeva S,Haghighi A,Turla ST,Mercola D.Inhibition of the Jun kinase pathway blocks DNA repair, enhances p53-mediated apoptosis and promotes gene amplification.Cell Growth Differ. 1999;10:545-54.
34. Scherer SJ,Maier SM,Seifert M, et al.p53 and c-Jun functionally synergize in the regulation of the DNA repair gene hMSH2 in response to UV.J Biol Chem. 2000;275:37469-73.
35. Weizman N,Shiloh Y,Barzilai A.Contribution of the ATM protein to maintaining cellular homeostasis evidenced by continuous activation of the AP-1 pathway in ATM-deficient brains.J Biol Chem. 2003;278:6741-7.
36. Bhoumik A,Takahashi S,Breitweiser W, et al.ATM-dependent phosphorylation of ATF2 is required for the DNA damage response.Mol Cell. 2005;18:577-87.
37. Xanthoudakis S,Curran T.Identification and characterization of Ref-1, a nuclear protein that facilitates AP-1 DNA-binding activity.EMBO J. 1992;11:653-65.
38. Chevray PM,Nathans D.Protein interaction cloning in yeast: identification of mammalian proteins that react with the leucine zipper of Jun.Proc Natl Acad Sci U S A. 1992;89:5789-93.
39. Grollman AP,Moriya M.Mutagenesis by 8-oxoguanine: an enemy within.Trends Genet. 1993;9:246-9.
40. Kim MJ,Choi SY,Park IC, et al.Opposing roles of c-Jun NH2-terminal kinase and p38 mitogen-activated protein kinase in the cellular response to ionizing radiation in human cervical cancer cells.Mol Cancer Res. 2008;6:1718-31.
41. Manning AM,Davis RJ.Targeting JNK for therapeutic benefit: from junk to gold?.Nat Rev Drug Discov. 2003;2:554-65.
42. Bain J,McLauchlan H,Elliott M,Cohen P.The specificities of protein kinase inhibitors: an update.Biochem J. 2003;371:199-204.
43. Santen RJ,Song RX,McPherson R, et al.The role of mitogen-activated protein (MAP) kinase in breast cancer.J Steroid Biochem Mol Biol. 2002;80:239-56.
44. Adjei AA.The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy.Clin Lung Cancer. 2005;7:221-3.
45. De Luca A,Maiello MR,D'Alessio A,Pergameno M,Normanno N.The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches.Expert Opin Ther Targets. 2012;16:S17-27.
46. de Bono JS,Rowinsky EK.Therapeutics targeting signal transduction for patients with colorectal carcinoma.Br Med Bull. 2002;64:227-54.
47. Bonner JA,Vroman BT,Christianson TJ,Karnitz LM.Ionizing radiation-induced MEK and Erk activation does not enhance survival of irradiated human squamous carcinoma cells.Int J Radiat Oncol Biol Phys. 1998;42:921-5.
48. Kasid U,Suy S,Dent P,Ray S,Whiteside TL,Sturgill TW.Activation of Raf by ionizing radiation.Nature. 1996;382:813-6.
49. Kharbanda S,Saleem A,Shafman T,Emoto Y,Weichselbaum R,Kufe D.Activation of the pp90 Rsk and mitogen-activated serine/threonine protein kinases by ionizing radiation.Proc Natl Acad Sci U S A. 1994;91:5416-20.
50. Sklar MD.The ras oncogenes increase the intrinsic resistance of NIH 3T3 cells to ionizing radiation.Science. 1988;239:645-7.
51. Bernhard EJ,Stanbridge EJ,Gupta S, et al.Direct evidence for the contribution of activated N-ras and K-ras oncogenes to increased intrinsic radiation resistance in human tumor cell lines.Cancer Res. 2000;60:6597-600.
52. McKenna WG,Bernhard EJ,Markiewicz DA,Rudoltz MS,Maity A,Muschel RJ.Regulation of radiation induced apoptosis in oncogene- transfected fibroblasts: influence of H-ras on the G2 delay.Oncogene. 1996;12:237-45.
53. Park JS,Qiao L,Su ZZ, et al.Ionizing radiation modulates vascular endothelial growth factor (VEGF) expression through multiple mitogen activated protein kinase dependent pathways.Oncogene. 2001;20:3266-80.
54. Byrne AM,Bouchier-Hayes DJ,Harmey JH.Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF).J Cell Mol Med. 2005;9:777-94.
55. Gorski DH,Beckett MA,Jaskowiak NT, et al.Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation.Cancer Res. 1999;59:3374-8.
56. Gupta VK,Jaskowiak NT,Beckett MA, et al.Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance.Cancer J. 2002;8:47-54.
57. Kim IA,Bae SS,Fernandes A, et al.Selective inhibition of Ras, phosphoinositide 3 kinase, and Akt isoforms increases the radiosensitivity of human carcinoma cell lines.Cancer Res. 2005;65:7902-10.
58. Bernhard EJ,Kao G,Cox AD, et al.The farnesyl transferase inhibitor FTI-277 radiosensitizes H-ras transformed rat embryo fibroblasts.Cancer Res. 1996;56:1727-30.
59. Kasid U,Pfeifer A,Brennan T, et al.Effect of antisense c-raf-1 on tumorigenicity and radiation sensitivity of a human squamous carcinoma.Science. 1989;243:1354-6.
60. Kohno M,Pouyssegur J.Targeting the ERK signaling pathway in cancer therapy.Ann Med. 2006;38:200-11.
61. Roskoski R.MEK1/2 dual-specificity protein kinases: structure and regulation.Biochem Biophys Res Commun. 2012;417:5-10.
62. Marampon F,Gravina GL,Di Rocco A, et al.MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.Mol Cancer Ther. 2011;10:159-68.
63. Sambade MJ,Camp JT,Kimple RJ,Sartor CI,Shields JM.Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf/MEK/ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.Radiother Oncol. 2009;93:639-44.
64. Kurland JF,Voehringer DW,Meyn RE.The MEK/ERK pathway acts upstream of NF kappa B1 (p50) homodimer activity and Bcl-2 expression in a murine B-cell lymphoma cell line: MEK inhibition restores radiation-induced apoptosis.J Biol Chem. 2003;278:32465-70.
65. Carter S,Auer KL,Reardon DB, et al.Inhibition of the mitogen activated protein (MAP) kinase cascade potentiates cell killing by low dose ionizing radiation in A431 human squamous carcinoma cells.Oncogene. 1998;16:2787-96.
66. Qiao L,Yacoub A,McKinstry R, et al.Pharmocologic inhibitors of the mitogen activated protein kinase cascade have the potential to interact with ionizing radiation exposure to induce cell death in carcinoma cells by multiple mechanisms.Cancer Biol Ther. 2002;1:168-76.
67. Chung EJ,Brown AP,Asano H, et al.In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase.Clin Cancer Res. 2009;15:3050-7.
68. Li J,Wang Y,Sun Y,Lawrence TS.Wild-type TP53 inhibits G(2)-phase checkpoint abrogation and radiosensitization induced by PD0166285, a WEE1 kinase inhibitor.Radiat Res. 2002;157:322-30.
69. Wang Y,Li J,Booher RN, et al.Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.Cancer Res. 2001;61:8211-7.
70. Abbott DW,Holt JT.Mitogen-activated protein kinase kinase 2 activation is essential for progression through the G2/M checkpoint arrest in cells exposed to ionizing radiation.J Biol Chem. 1999;274:2732-42.
71. Iliakis G,Nusse M.Arrest of irradiated G1, S, or G2 cells at mitosis using nocodazole promotes repair of potentially lethal damage.Radiat Res. 1984;99:346-51.
72. Tamamoto T,Ohnishi K,Takahashi A, et al.Correlation between γ-ray-induced G2 arrest and radioresistance in two human cancer cells.Int J Radiat Oncol Biol Phys. 1999;44:905-9.
73. Huang H,Fletcher L,Beeharry N, et al.Abnormal cytokinesis after X-irradiation in tumor cells that override the G2 DNA damage checkpoint.Cancer Res. 2008;68:3724-32.
74. Eriksson D,Lofroth PO,Johansson L,Riklund KA,Stigbrand T.Cell cycle disturbances and mitotic catastrophes in HeLa Hep2 cells following 2.5 to 10 Gy of ionizing radiation.Clin Cancer Res. 2007;13:5501-8.
75. Syljuasen RG,Sorensen CS,Nylandsted J,Lukas C,Lukas J,Bartek J.Inhibition of Chk1 by CEP-3891 accelerates mitotic nuclear fragmentation in response to ionizing radiation.Cancer Res. 2004;64:9035-40.
76. Wei F,Yan J,Tang D, et al.Inhibition of ERK activation enhances the repair of double-stranded breaks via non-homologous end joining by increasing DNA-PKcs activation.Biochim Biophys Acta. 2013;1833:90-100.
77. Golding SE,Morgan RN,Adams BR,Hawkins AJ,Povirk LF,Valerie K.Pro-survival AKT and ERK signaling from EGFR and mutant EGFRvIII enhances DNA double-strand break repair in human glioma cells.Cancer Biol Ther. 2009;8:730-8.
78. Golding SE,Rosenberg E,Neill S,Dent P,Povirk LF,Valerie K.Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response.Cancer Res. 2007;67:1046-53.
79. Hamed H,Hawkins W,Mitchell C, et al.Transient exposure of carcinoma cells to RAS/MEK inhibitors and UCN-01 causes cell death in vitro and in vivo.Mol Cancer Ther. 2008;7:616-29.
80. Williams TM,Flecha AR,Keller P, et al.Cotargeting MAPK and PI3K signaling with concurrent radiotherapy as a strategy for the treatment of pancreatic cancer.Mol Cancer Ther. 2012;11:1193-202.
81. Marampon F,Gravina GL,Di Rocco A, et al.MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals.Mol Cancer Ther. 2011;10:159-68.
82. Shannon AM,Telfer BA,Smith PD, et al.The mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) enhances the radiation responsiveness of lung and colorectal tumor xenografts.Clin Cancer Res. 2009;15:6619-29.
83. Lorusso PM,Adjei AA,Varterasian M, et al.Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies.J Clin Oncol. 2005;23:5281-93.
84. Rinehart J,Adjei AA,Lorusso PM, et al.Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer.J Clin Oncol. 2004;22:4456-62.
85. Solit DB,Garraway LA,Pratilas CA, et al.BRAF mutation predicts sensitivity to MEK inhibition.Nature. 2006;439:358-62.
86. Infante JR,Fecher LA,Falchook GS, et al.Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial.Lancet Oncol. 2012;13:773-81.
87. Falchook GS,Lewis KD,Infante JR, et al.Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial.Lancet Oncol. 2012;13:782-9.
88. Flaherty KT,Robert C,Hersey P, et al.Improved survival with MEK inhibition in BRAF-mutated melanoma.N Engl J Med. 2012;367:107-14.
89. Han J,Lee JD,Bibbs L,Ulevitch RJ.A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells.Science. 1994;265:808-11.
90. Lin A,Minden A,Martinetto H, et al.Identification of a dual specificity kinase that activates the Jun kinases and p38-Mpk2.Science. 1995;268:286-90.
91. Holbrook NJ,Liu Y,Fornace AJ.Signaling events controlling the molecular response to genotoxic stress.EXS. 1996;77:273-88.
92. Lee SH,Eom M,Lee SJ,Kim S,Park HJ,Park D.BetaPix-enhanced p38 activation by Cdc42/Rac/PAK/MKK3/6-mediated pathway: implication in the regulation of membrane ruffling.J Biol Chem. 2001;276:25066-72.
93. Maizels ET,Mukherjee A,Sithanandam G, et al.Developmental regulation of mitogen- activated protein kinase-activated kinases-2 and -3 (MAPKAPK-2/-3) in vivo during corpus luteum formation in the rat.Mol Endocrinol. 2001;15:716-33.
94. Deak M,Clifton AD,Lucocq LM,Alessi DR.Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB.EMBO J. 1998;17:4426-41.
95. Wiggin GR,Soloaga A,Foster JM,Murray-Tait V,Cohen P,Arthur JS.MSK1 and MSK2 are required for the mitogen- and stress-induced phosphorylation of CREB and ATF1 in fibroblasts.Mol Cell Biol. 2002;22:2871-81.
96. Juretic N,Santibáñez JF,Hurtado C,Martínez J.ERK 1, 2 and p38 pathways are involved in the proliferative stimuli mediated by urokinase in osteoblastic SaOS-2 cell line.J Cell Biochem. 2001;83:92-8.
97. Yosimichi G,Nakanishi T,Nishida T,Hattori T,Takano-Yamamoto T,Takigawa M.CTGF/Hcs24 induces chondrocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extracellular-signal regulated kinase (ERK).Eur J Biochem. 2001;268:6058-65.
98. Kim SJ,Ju JW,Oh CD, et al.ERK-1/2 and p38 kinase oppositely regulate nitric oxide-induced apoptosis of chondrocytes in association with p53, caspase-3, and differentiation status.J Biol Chem. 2002;277:1332-9.
99. Taher MM,Hershey CM,Oakley JD,Valerie K.Role of the p38 and MEK-1/2/p42/44 MAP kinase pathways in the differential activation of human immunodeficiency virus gene expression by ultraviolet and ionizing radiation.Photochem Photobiol. 2000;71:455-9.
100. Lee YJ,Soh JW,Dean NM, et al.Protein kinase C delta over expression enhances radiation sensitivity via extracellular regulated protein kinase 1/2 activation, abolishing the radiation-induced G(2)-M arrest.Cell Growth Differ. 2002;13:237-46.
101. Narang H,Bhat N,Gupta SK, et al.Differential activation of mitogen-activated protein kinases following high and low LET radiation in murine macrophage cell line.Mol Cell Biochem. 2009;324:85-91.
102. Wang X,McGowan CH,Zhao M, et al.Involvement of the MKK6-p38gamma cascade in gamma-radiation-induced cell cycle arrest.Mol Cell Biol. 2000;20:4543-52.
103. Bulavin DV,Amundson SA,Fornace AJ.p38 and Chk1 kinases: different conductors for the G(2)/M checkpoint symphony.Curr Opin Genet Dev. 2002;2:92-7.
104. Choi SY,Kim MJ,Kang CM, et al.Activation of Bak and Bax through c-abl-protein kinase Cdelta-p38 MAPK signaling in response to ionizing radiation in human non-small cell lung cancer cells.J Biol Chem. 2006;281:7049-59.
105. Dominguez C,Powers DA,Tamayo N.p38 MAP kinase inhibitors: many are made, but few are chosen.Curr Opin Drug Discov Devel. 2005;8:421-30.
106. Hynes J,Leftheri K.Small molecule p38 inhibitors: novel structural features and advances from 2002-2005.Curr Top Med Chem. 2005;5:967-85.
107. O'Neill LA.Targeting signal transduction as a strategy to treat inflammatory diseases.Nat Rev Drug Discov. 2006;5:549-63.